| 1 |
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
|
| 2 |
Torre LA, Siegel RL, Ward EM, et al. Global Cancer Incidence and Mortality Rates and Trends-An Update[J]. Cancer Epidemiol Biomarkers Prev, 2016, 25(1): 16-27.
|
| 3 |
Tan CS, Kumarakulasinghe NB, Huang YQ, et al. Third generation EGFR TKIs: current data and future directions [J]. Mol Cancer, 2018, 17(1): 29.
|
| 4 |
Hattrup CL, Gendler SJ. Structure and Function of the Cell Surface (Tethered) Mucins[J]. Annu Rev Physiol, 2008, 70(1): 431-457.
|
| 5 |
Levitin F, Stern O, Weiss M, et al. The MUC1 SEA Module Is a Self-cleaving Domain[J]. J Biol Chem, 2005, 280(39): 33374-33386.
|
| 6 |
Nath S, Mukherjee P. Muc1: a multifaceted oncoprotein with a key role in cancer progression[J]. Trends Mol Med, 2014, 20(6): 332-342.
|
| 7 |
Itoh Y, Kamata-Sakurai M, Denda-Nagai K, et al. Identification and expression of human epiglycanin/MUC21: a novel transmembrane mucin[J]. Glycobiology, 2008, 18(1): 74-83.
|
| 8 |
Andrianifahanana M, Moniaux N, Batra SK. Regulation of mucin expression: mechanistic aspects and implications for cancer and inflammatory diseases[J]. Bioch Biophys Acta, 2006, 1765(2): 189-222.
|
| 9 |
Gendler SJ. MUC1, The Renaissance Molecule[J]. J Mammary Gland Biol Neopl, 2001, 6(3): 339-353.
|
| 10 |
Ham SY, Kwon T, Bak Y, et al. Mucin 1-mediated chemo-resistance in lung cancer cells[J]. Oncogenesis, 2016, 5(1): e185.
|
| 11 |
Kong X, Ding LJ, Wang ZX. Mucin expression profile of benign and malignant cervical tissues and correlation with clinical-pathologic parameters[J]. Eur J Gynaecol Oncol, 2017, 38(3): 350-355.
|
| 12 |
Sun ZG, Yu L, Gao W, et al. Clinical and prognostic significance of MUC1 expression in patients with esophageal squamous cell carcinoma after radical resection[J]. Saudi J Gastroenterol, 2018, 24(3): 165-170.
|
| 13 |
Wang X, Che X, Liu C, et al. Cancer-associated fibroblasts-stimulated interleukin-11 promotes metastasis of gastric cancer cells mediated by upregulation of MUC1[J]. Exp Cell Res, 2018, 368(2): 184-193.
|
| 14 |
Situ D, Wang J, Ma Y, et al. Expression and prognostic relevance of MUC1 in stage IB non-small cell lung cancer[J]. Med Oncol, 2011, 28(1): 596-604.
|
| 15 |
Xu T, Li D, Wang H, et al. MUC1 downregulation inhibits non-small cell lung cancer progression in human cell lines[J]. Exp Ther Med, 2017, 14(5): 4443-4447.
|
| 16 |
Kaira K, Okumura T, Nakagawa K, et al. MUC1 expression in pulmonary metastatic tumors: a comparison of primary lung cancer[J]. Pathol Oncol Res, 2012, 18(2): 439-447.
|
| 17 |
Altschuler Y, Kinlough CL, Poland PA, et al. Clathrin-mediated endocytosis of MUC1 is modulated by its glycosylation state[J]. Mol Biol Cell, 2000, 11(3): 819-831.
|
| 18 |
Cascio S, Zhang L, Finn OJ. MUC1 Protein Expression in Tumor Cells Regulates Transcription of Proinflammatory Cytokines by Forming a Complex with Nuclear Factor-κB p65 and Binding to Cytokine Promoters importance of extracellular domain[J]. J Biol Chem, 2011, 286(49): 42248-42256.
|
| 19 |
Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition[J]. J Clin Invest, 2015, 119(6): 1420-1428.
|
| 20 |
Mori Y, Akita K, Yashiro M, et al. Binding of Galectin-3, a β-Galactoside-binding Lectin, to MUC1 Protein Enhances Phosphorylation of Extracellular Signal-regulated Kinase 1/2 (ERK1/2) and Akt, Promoting Tumor Cell Malignancy[J]. J Bio Chem, 2015, 290(43): 26125-26140.
|
| 21 |
Behrens ME, Grandgenett PM, Bailey JM, et al. The reactive tumor microenvironment: MUC1 signaling directly reprograms transcription of CTGF[J]. Oncogene, 2010, 29(42): 5667-5677.
|
| 22 |
Besmer DM, Curry JM, Roy LD, et al. Pancreatic ductal adenocarcinoma mice lacking mucin 1 have a profound defect in tumor growth and metastasis[J]. Cancer Res, 2011, 71(13): 4432-4442.
|
| 23 |
Min X, Tao W. Upregulation of MUC1 by its novel activator 14-3-3ζ promotes tumor invasion and indicates poor prognosis in lung adenocarcinoma[J]. Oncology Rep, 2017, 38(5): 2637-2646.
|
| 24 |
Tagde A, Rajabi H, Bouillez A, et al. MUC1-C drives MYC in multiple myeloma[J]. Blood, 2016, 127(21): 2587-2597.
|
| 25 |
付红艳，王义勇，张科东，等. MUC1蛋白在非小细胞肺癌早期诊断中的临床价值[J]. 天津医药，2019, 47(10): 1050-1053.
|
| 26 |
蒋平平，李 冬，杨 凡. 血MUC1 mRNA和cyfra21-1蛋白对非小细胞肺癌的诊断价值[J]. 临床与病理杂志，2017(11): 2395-2401.
|
| 27 |
Xu F, Liu F, Zhao H, et al. Prognostic Significance of Mucin Antigen MUC1 in Various Human Epithelial Cancers：A Meta-Analysis[J]. Medicine, 2015, 94(50): e2286.
|
| 28 |
Tomita M, Ayabe T, Chosa E, et al. Prognostic Significance of a Tumor Marker Index Based on Preoperative Serum Carcinoembryonic Antigen and Krebs von den Lungen-6 Levels in Non-Small Cell Lung Cancer[J]. Asian Pac J Cancer Prev, 2017, 18(1): 287-291.
|
| 29 |
Huang X, Sun Q, Chen C, et al. MUC1 overexpression predicts worse survival in patients with non-small cell lung cancer: evidence from an updated meta-analysis[J]. Oncotarget, 2017, 8(52): 90315-90326.
|
| 30 |
Antonarakis ES, Small EJ, Petrylak DP, et al. Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall Survival[J]. Clin Cancer Res, 2018, 24(19): 4662-4671.
|
| 31 |
Arriola E, Ottensmeier C. TG4010: a vaccine with a therapeutic role in cancer[J]. Immunotherapy, 2016, 8(5): 511-519.
|
| 32 |
Rochlitz C, Figlin R, Squiban P, et al. Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer[J]. J Gene Med, 2003, 5(8): 690-699.
|
| 33 |
Quoix E, Ramlau R, Westeel V, et al. Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial[J]. Lancet Oncol, 2011, 12(12): 1125-1133.
|
| 34 |
Quoix E, Lena H, Losonczy G, et al. TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial[J]. Lancet Oncol, 2016, 17(2): 212-223.
|
| 35 |
Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial[J]. Lancet, 2015, 387(10027): 1540-1550.
|
| 36 |
Tosch C, Bastien B, Barraud L, et al. Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC[J]. J Immunother Cancer, 2017, 5(1): 70.
|
| 37 |
Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer[J]. N Engl J Med, 2016, 375(19): 1823-1833.
|
| 38 |
Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle[J]. Immunity, 2013, 39(1): 1-10.
|
| 39 |
Remyziller C, Thioudellet C, Hortelano J, et al. Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model[J]. Hum Vaccin Immunother, 2018, 14(1): 140-145.
|
| 40 |
Liu C, Lu Z, Xie Y, et al. Soluble PD-1-based vaccine targeting MUC1 VNTR and survivin improves anti-tumor effect[J]. Immunol Lett, 2018, 200: 33-42.
|
| 41 |
Sangha R, Butts C. L-BLP25: A Peptide Vaccine Strategy in Non-Small Cell Lung Cancer[J]. Clin Cancer Res, 2007, 13(2): 4652-4654.
|
| 42 |
Ioannides CG, Fisk B, Jerome KR, et al. Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides[J]. J Immunol, 1993, 151(7): 3693-3703.
|
| 43 |
Avichezer D, Taylor-Papadimitriou J, Arnon R. A short synthetic peptide (DTRPAP) induces anti-mucin (MUC-1) antibody, which is reactive with human ovarian and breast cancer cells[J]. Cancer Biochem Biophys, 1998, 16(1-2): 113-128.
|
| 44 |
Agrawal B, Krantz MJ, Reddish MA, et al. Rapid induction of primary human CD4+ and CD8+ T cell responses against cancer-associated MUC1 peptide epitopes[J]. Int Immunol, 1998, 10(12): 1907-1916.
|
| 45 |
Palmer M, Parker J, Modi S, et al. Phase Ⅰ Study of the BLP25 (MUC1 Peptide) Liposomal Vaccine for Active Specific Immunotherapy in Stage ⅢB/Ⅳ non-small-cell lung cancer[J]. Clin Lung Cancer, 2002, 3(1): 49-57.
|
| 46 |
Ohyanagi F, Horai T, Sekine I, et al. Safety of BLP25 liposome vaccine (L-BLP25) in Japanese patients with unresectable stage Ⅲ NSCLC after primary chemoradiotherapy: preliminary results from a Phase Ⅰ/Ⅱ study[J]. Jpn J Oncol, 2011, 41(5): 718-722.
|
| 47 |
Butts C, Murray N, Maksymiuk A, et al. Randomized phase ⅡB trial of BLP25 liposome vaccine in stage ⅢB and Ⅳ non-small-cell lung cancer[J]. J Clin Oncol, 2005, 23(27): 6674-6681.
|
| 48 |
Butts C, Socinski MA, Mitchell PL, et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage Ⅲ non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial[J]. Lancet Oncol, 2014, 15(1): 59-68.
|
| 49 |
Katakami N, Hida T, Nokihara H, et al. Phase Ⅰ/Ⅱ study of tecemotide as immunotherapy in Japanese patients with unresectable stage Ⅲ non-small cell lung cancer[J]. Lung Cancer, 2017, 105: 23-30.
|